Skip to main content

Table 2 Clinical use of taurine in different pathophysiological conditions

From: Taurine: the appeal of a safe amino acid for skeletal muscle disorders

References Patients Dose (g/day or mg/kg) Duration Result
Franconi et al. [130] IDDM (Diabetes mellitus type 1) 1.5 g 90 days No effect
Elizarova and Nedosugova [131] IDDM 1 g 30 days Glucose metabolism and trygliceride level improved
Chauncey et al. [133] NIDDM (DM type 2) 3 g 4 months Plasma taurine level increased
Brøns et al. [134] Overweight non-diabetic 1.5 g 8 weeks No effect
Xiao et al. [136] Overweight non-diabetic 3 g 2 weeks Insulin sensitivity improved
Nakamura et al. [132] NIDDM with microalbuminemia 3 g 12 months No effect
Moloney et al. [135] IDDM 1.5 g 2 weeks Endotelium-dependent reaction improved
Gonzales-Contreras et al. [142] Cholestasis by parenteral nutrition ~25 mg/kg/day ~50 days Hepatoprotection with reduction of AST, ALT and GGT
Rosa et al. [143] Obesity 3 g/day 8 weeks Increase in plasma levels of taurine and adiponectin; reduction of inflammatory markers
Pearl et al. [141] Succinic semialdehyde dehydrogenase deficiency (efficacy, safety and tolerability) 50–200 mg/kg/d (age range 12 years) 13 months (mean time from 3 to 50) No significant effects
Tolerability issues at highest doses
Fujita et al. [139] Hypertension 6 g 7 days Systolic and diastolic pressure improved
Azuma et al. [138] Congestive heart failure 6 g 4 weeks Heart parameters improved
Bergamini et al. [137] Epilepsy 200 mg–21 g Various Seizure frequency reduction
Durelli et al. [36] Dystrophic myotonia 6–10 g 6 months Myotonic symptoms improvement
Dunn-Lewis et al. [140] Elderly 500 mg in multinurtient supplement 4 weeks Physical function improved